2024 Compounding Diabetes 
Express Pharma
JANUARY 14, 2025
Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. per cent from 2024 to 2030. billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3 billion in 2023 and is expected to grow at a CAGR of 8.4
European Pharmaceutical Review
JUNE 5, 2024
As such, the compound annual growth rate (CAGR) is expected to be 12.8 million deaths from diabetes” worldwide. Europe will be the fastest-growing region in the [small molecule injectable drugs] market between 2024 and 2033″ The report predicted that Europe will be the fastest-growing region in the market between 2024 and 2033.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
MAY 30, 2024
The World Health Organization stated in March 2024 that “over 80 per cent of neurological deaths and health losses occur in low- and middle-income countries, and access to treatment varies widely.” billion in 2030, with a compound annual growth rate (CAGR) of 117.6 These include Eisai Co. per cent.
PharmaShots
FEBRUARY 22, 2023
Approved Indications of Trulicity2 Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to diet and exercise to improve glycaemic control in adults and paediatric patients (age: ≥10 years) with type 2 diabetes mellitus. million patients’ journeys with type 2 diabetes since 2014.
RX Note
FEBRUARY 4, 2024
Introduction In parallel with industrialization, the focus of pharmacists' practice has evolved from compounding and dispensing medications to the provision of professional services for patients. As experts in medicines, pharmacists can review complex medicine regimens and identify causes of problems and resolve them. Watson et al.
pharmaphorum
AUGUST 19, 2022
The drug works via the same target as capsaicin, a compound found in chilli peppers that is used in some topical formulations for pain relief in arthritis and other conditions, but is much more potent. It will recruit people with osteoarthritis who have exhausted other treatment options but are still experiencing moderate to severe pain. .
Big Molecule Watch
SEPTEMBER 24, 2024
On September 3, 2024, Eli Lilly filed a complaint against the FDA in the District Court for the Southern District of Indiana pursuing the latest challenge to the FDA’s application of its “biological product” classification. 2024), the D.C. See Eli Lilly & Co. Becerra et al. , 1:24-cv-01503 (S.D. 42 U.S.C. § 3d 66 (D.D.C
Expert insights. Personalized for you.
105 
Let's personalize your content